Furthermore, several RCTs in adults with overweight or obesity have evaluated other multi-receptor drugs, such as Retatrutide, which targets GIPR/Glucagon receptor (GCGR)/GLP-1R, and Mazdutide, which targets GCGR/GLP-1R, showing promising results in both glycemic management and weight reduction (14–17). This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.